NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.

$2.86
As of 02/26/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
Switzerland

01/28/2021
10,596,363
485,788
$30,305,598
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
-4.13
0.00
0.00%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy